Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Ampronix

Simplified Alzheimer’s Disease Diagnosis Using PET Imaging and More Effective Criteria

By Medimaging International staff writers
Posted on 24 Jul 2014
Print article
According to French investigators, over one-third of patients receive an incorrect diagnosis of Alzheimer’s disease (AD). To reduce the number of errors, the diagnostic criteria available must be the most reliable possible, especially at the very early stages of the disease. For the past 10 years, an international team of neurologists has been working towards this objective. The researchers recently introduced new diagnostic criteria, in particular, biomarkers. These are authentic signatures of the disease, and are present from the first symptoms (prodromal stage).

In the June 2014 issue of the Lancet Neurology journal, Dr. Bruno Dubois, from the National de la Santé et de la Recherche Médicale (Inserm; Paris, France) and Pierre and Marie Curie University (Paris, France) /AP-HP Joint Research Unit 975) and colleagues have developed a simplified diagnosis based on the most specific criteria of the disease, which should have a major impact in clinical practice.

AD is the most common (70%) form of dementia. The real challenge of a definitive diagnosis is to know how to differentiate this disease from other types of dementia, and establish the diagnosis as effectively and as early as possible.

In 2005, an international group of neurologists, coordinated by Inserm’s Dr. Bruno Dubois, came together to redefine the diagnostic criteria established in 1984. Up to then, it had been necessary to await the death of a patient in order to establish a diagnosis of AD with certainty by examining the lesions in his/her brain. And in the living, only a probability of disease could be inferred, and only at a late stage, based on a certain threshold of severity of dementia.

In 2007, the international team broke these hypotheses apart. The researchers introduced new diagnostic criteria, particularly biomarkers. These are authentic signatures of the disease, and are present from the initial symptoms (prodromal stage). The publication of these findings initiated a transformation. Researchers then observed that with these new criteria, “36% of their patients included in a therapeutic trial based on previous clinical criteria did not have Alzheimer’s disease,” reported Prof. Dubois. However, although this analysis involved only a subgroup of patients, the implications are serious. Patients did not receive the correct treatment and/or care. Moreover, flawed patient selection might have had an impact on the lack of efficacy observed for the new treatment.

Since 2007, many studies have been published. The international group decided to analyze this literature to make the diagnostic algorithm for AD simpler and more reliable. “We have reached the end of the road; we have arrived at the essence, something refined, resulting from an international consensus,” indicated Prof. Dubois. The diagnosis of Alzheimer’s disease will henceforth rely on “just a couple of clinical-biological criteria for all stages of the disease.”

Most of the time, the diagnosis of AD is based primarily on a suggestive clinical picture. It is subsequently confirmed or rejected using a biomarker. As regards the clinical picture, there are three scenarios: (1) typical cases (80%–85% of all cases): impairment of episodic long-term memory (known as amnestic syndrome of the hippocampal type and corresponding to difficulty remembering a list a words, even with clues, for example); (2) atypical cases (15%–20% of cases): atrophy of the posterior part of the cerebral cortex or logopenic aphasia (impairment of verbal memory where the patient inverts the syllables of a word when repeating it, for example), or frontal brain damage, which results in behavioral problems; (3) preclinical states: asymptomatic at-risk (patients without symptoms, but who are fortuitously discovered to have positive biomarkers during scientific studies), and presymptomatic (with a genetic mutation).

One of the following two biomarkers is required: (1) in the cerebrospinal fluid (obtained by lumbar puncture) to ascertain abnormal levels of brain proteins (reduced beta amyloid protein and increased tau protein); (2) and in the brain by positron emission tomography (PET) neuroimaging to determine the elevated retention of amyloid tracer.

This simpler and more effective algorithm is important, mainly for research (therapeutic trials, characterization of the disease, monitoring of patient cohorts), according to the investigators. Outside of research, the use of biomarkers, which is expensive and/or invasive, currently remains limited to young patients or difficult or complex cases in specialty centers.

Related Links:
National de la Santé et de la Recherche Médicale
Pierre and Marie Curie University




Print article
Radcal

Channels

MRI

view channel
Image: The results of MRI scans are expected to inform future clinical guidelines for heart disease (Photo courtesy of the University of Leeds).

MRI Helps Identify High-Risk Heart Disease Patients

A new study concludes that magnetic resonance imaging (MRI) scans are the safest and most effective way to identify patients with suspected coronary heart disease (CHD). Researchers at the University... Read more

General/Advanced Imaging

view channel
Image: Emory radiologists reduce Phantom Limb Pain (PLP) by applying a new non-invasive cryoablation procedure (Photo courtesy of Kevin Makowski, RBP).

Radiologists Demonstrate Minimally Invasive Procedure that can Freeze Phantom Limb Pain

Researchers have presented the results of a study investing the use of cryoablation to reduce Phantom Limb Pain (PLP) in patients with chronic pain in amputated limbs. The researchers showed that interventional... Read more

Imaging IT

view channel

Latest Release of Enterprise Imaging Platform Demonstrated at ACR 2016

A global enterprise diagnostic imaging and advanced visualization solutions provider has demonstrated the latest release of their Enterprise Imaging Platform that features thin-client, server-side processing, and simple diagnostic mobile access. The manufacturer made the announcement at the annual meeting of the American... Read more

Industry News

view channel

UK Health Service to Spend GBP 21.5 Million Upgrading Radiotherapy Resources

The UK’s National Health Service has agreed to acquire linear accelerators, and software from a human care company in a deal valued at GBP 21.5 million. The order includes linear accelerators (linacs), multileaf collimators, and a system for improving the speed and reducing the radiation dose of radiation therapy treatment.... Read more
Copyright © 2000-2016 Globetech Media. All rights reserved.